文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

JAK2 V617F突变及相关染色体改变在原发性和继发性骨髓纤维化及移植后结局中的意义

JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.
PubMed 文献 · Blood Adv · 2023-01-01

研究纳入2000至2016年间接受异基因造血细胞移植(HCT)且有移植前血样的973例骨髓纤维化患者,用PacBio测序和SNP阵列检测JAK2V617F及镶嵌染色体改变(mCA)。在原发性骨髓纤维化中,JAK2V617F状态、等位基因负荷或mCA与疾病进展/复发、非复发死亡(NRM)或总生存均无关联;在继发于原发性血小板增多症的骨髓纤维化中,高突变等位基因负荷(≥60%)与NRM风险增加相关,仅限于JAK抑制剂时代(2013-2016年)的移植。

要点

  • JAK2V617F见于57.6%的原发性骨髓纤维化、97%的继发于真性红细胞增多症的骨髓纤维化和42.6%的继发于原发性血小板增多症的骨髓纤维化。
  • 在原发性骨髓纤维化中,JAK2V617F状态、等位基因负荷或mCA与移植后结局无关联。
  • 在继发于原发性血小板增多症的骨髓纤维化中,JAK2V617F高等位基因负荷(≥60%)与NRM风险增加相关(HR=7.65,95%CI 2.10-27.82,P=.002),仅限于2013-2016年移植。

核心结论

  • 研究结果支持HCT可减轻JAK2V617F对骨髓纤维化患者已知不良影响的观点,尤其是对原发性和继发于真性红细胞增多症的骨髓纤维化。

研究设计与样本

  • 研究纳入2000至2016年间接受HCT且有移植前血样储存于国际血液与骨髓移植研究中心生物样本库的973例骨髓纤维化患者,其中924例基因组检测完整(634例原发性骨髓纤维化、135例继发于真性红细胞增多症的骨髓纤维化、155例继发于原发性血小板增多症的骨髓纤维化)。

主要发现

  • JAK2V617F影响562例患者(原发性骨髓纤维化57.6%、继发于真性红细胞增多症的骨髓纤维化97%、继发于原发性血小板增多症的骨髓纤维化42.6%)。
  • 涉及JAK2区域的mCA患者中97.9%为JAK2V617F阳性。
  • 在原发性骨髓纤维化中,JAK2V617F突变状态、等位基因负荷或检出的mCA与疾病进展/复发、非复发死亡或总生存均无关联。
  • 在继发于原发性血小板增多症的骨髓纤维化中,JAK2V617F高突变等位基因负荷(≥60%)与NRM风险增加相关,仅限于JAK抑制剂时代(2013-2016年)的移植(HR=7.65,95%CI 2.10-27.82,P=.002);等位基因负荷与移植后疾病进展/复发或生存无关联。

关键数值与推荐

  • JAK2V617F高突变等位基因负荷定义为≥60%。
  • 在继发于原发性血小板增多症的骨髓纤维化中,高等位基因负荷(≥60%)与NRM风险增加相关(HR=7.65,95%CI 2.10-27.82,P=.002),仅限于2013-2016年移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

JAK2 V617F is the most common driver mutation in primary or secondary myelofibrosis for which allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment. Knowledge of the prognostic utility of JAK2 alterations in the HCT setting is limited. We identified all patients with MF who received HCT between 2000 and 2016 and had a pre-HCT blood sample (N = 973) available at the Center of International Blood and Marrow Transplant Research biorepository. PacBio sequencing and single nucleotide polymorphism-array genotyping were used to identify JAK2V617F mutation and associated mosaic chromosomal alterations (mCAs), respectively. Cox proportional hazard models were used for HCT outcome analyses. Genomic testing was complete for 924 patients with MF (634 primary MF [PMF], 135 postpolycythemia vera [PPV-MF], and 155 postessential thrombocytopenia [PET-MF]). JAK2V617F affected 562 patients (57.6% of PMF, 97% of PPV-MF, and 42.6% of PET-MF). Almost all patients with mCAs involving the JAK2 region (97.9%) were JAK2V617-positive. In PMF, JAK2V617F mutation status, allele burden, or identified mCAs were not associated with disease progression/relapse, nonrelapse mortality (NRM), or overall survival. Almost all PPV-MF were JAK2V617F-positive (97%), with no association between HCT outcomes and mutation allele burden or mCAs. In PET-MF, JAK2V617F high mutation allele burden (≥60%) was associated with excess risk of NRM, restricted to transplants received in the era of JAK inhibitors (2013-2016; hazard ratio = 7.65; 95% confidence interval = 2.10-27.82; P = .002). However, allele burden was not associated with post-HCT disease progression/relapse or survival. Our findings support the concept that HCT can mitigate the known negative effect of JAK2V617F in patients with MF, particularly for PMF and PPV-MF.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rafati M, Brown DW, Zhou W, et al. JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes. Blood Adv. 2023. PMID: 38011490. doi:10.1182/bloodadvances.2023010882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。